In ACCORD Lipid, fenofibrate also reduced micro - and macro-albuminuria, markers of diabetic renal disease.

在ACCORD脂质研究基金会，非诺贝特同时降低了微观及宏观尿蛋白量，二者都是胰岛肾病的标志。